DaVita (DVA)
(Delayed Data from NYSE)
$164.11 USD
+2.54 (1.57%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $164.11 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value C Growth C Momentum B VGM
Price, Consensus and EPS Surprise
DVA 164.11 +2.54(1.57%)
Will DVA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DVA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DVA
VEEV Stock Down Despite Expansion of Vault QMS to Boost Patient Safety
Reasons to Retain Intuitive Surgical Stock in Your Portfolio Now
DVA: What are Zacks experts saying now?
Zacks Private Portfolio Services
DaVita HealthCare (DVA) Stock Sinks As Market Gains: What You Should Know
Senseonics Stock Down Despite New FDA Approval for Eversense 365
Are You Looking for a Top Momentum Pick? Why DaVita HealthCare (DVA) is a Great Choice
Other News for DVA
Stocks that are expected to benefit from lower fed funds rate and a softer labor market
DaVita Inc (DVA) CEO Javier Rodriguez Sells 59,881 Shares
DaVita Accelerates Commitment to Community Health with Nationwide Tour
Moderna was most shorted S&P 500 healthcare stock in August for second consecutive month
IHF: Healthcare Dashboard For September